Summary — H.R. 307 (as provided): "Amputation Reduction and Compassion Act of 2025" (ARC Act of 2025) — and related materials
Note on source materials
- The file provided mixes multiple, distinct texts labeled “H.R. 307,” including (a) a federal-style bill titled the Amputation Reduction and Compassion Act of 2025 (ARC Act) containing congressional findings about peripheral artery disease (PAD); and (b) several unrelated state legislative resolutions (commendations, facility renamings, memorials) and varied procedural entries. This summary focuses on the substantive federal proposal (the ARC Act), and then notes procedural and document ambiguities. For final legal status or operative provisions, consult the official bill text and Congressional records.
Purpose and intent
- The ARC Act of 2025 aims to raise awareness of peripheral artery disease (PAD), promote routine screening and evidence‑based care, and reduce avoidable amputations and PAD‑related deaths—particularly among demographic groups experiencing disproportionate harm.
Key findings and rationale (selected highlights from the bill)
- Atherosclerosis reduces blood flow by arterial narrowing; it causes more deaths in the U.S. than any other condition; coronary atherosclerosis causes most heart attacks.
- PAD is atherosclerosis of the legs; it substantially increases risks of heart attack, stroke, amputation, and death.
- Approximately 21 million Americans have PAD; roughly 200,000 people—disproportionately from minority communities—suffer avoidable amputations each year due to PAD.
- Racial and ethnic disparities: among people with diabetes, African Americans face amputation risks up to four times the national average; Native Americans more than twice as likely; Hispanics up to 75% more likely to undergo amputation.
- Mortality after amputation is high: ~52% of patients with above‑knee amputations and ~33% with below‑knee amputations die within two years.
- Screening and arterial testing for PAD are cost‑effective and should be part of routine care; PAD diagnosis is associated with a 67% increase in risk of cardiac death, so detection enables earlier cardiac risk reduction.
- Use of national, evidence‑based PAD care guidelines can reduce amputations and deaths.
Key provisions (limitations)
- The provided text contains only the bill’s short title and the congressional findings; it does not include operative sections (e.g., program authorizations, funding levels, reporting requirements, screening protocols, or federal agency responsibilities).
- Because operative language is not present, specific policy changes (such as Medicare/Medicaid coverage changes, grant programs, public awareness campaigns, or clinical guideline mandates) cannot be confirmed from the supplied document.
Who would be affected
- Patients with PAD or at high risk for PAD (older adults, people with diabetes or smoking history).
- Racial and ethnic minority communities experiencing higher amputation rates.
- Health care providers and health systems (if the bill leads to new screening, testing, guideline implementation, or quality metrics).
- Payors and federal health programs (if the final bill includes coverage, reimbursement, or programmatic changes).
Procedural status and sponsors (as provided)
- Introduced: January 9, 2025.
- Referred to the House Committee on Energy and Commerce and to the Committee on Ways and Means (for provisions within their jurisdictions).
- Sponsor data in the file is inconsistent and includes many named members (e.g., LaMonica McIver listed as primary and numerous cosponsors such as Raúl Grijalva, Lloyd Doggett, etc.). Because the packet mixes multiple resolutions and jurisdictions, verify sponsors in the official Congressional bill record.
- The document also includes numerous procedural entries (laid before the House, adopted, enrolled, presented to Secretary of State) that appear to conflate federal and state actions; these entries create uncertainty about final status and must be checked against official House records.
Bottom line / recommended next steps
- The ARC Act’s findings emphasize the public‑health importance of PAD, its disproportionate impact on minority communities, the high mortality after amputation, and the cost‑effectiveness of screening and guideline‑based care.
- However, the supplied document lacks the bill’s operative sections. To determine concrete impacts (funding, new programs, coverage mandates, or regulatory changes), review the full bill text and committee reports available from Congress.gov or the House Clerk’s office and confirm the official sponsor/cosponsor list and legislative status.
